# EDGAR Filing Document

**Accession Number:** 0001891512
**File Stem:** 0001062993-23-007273
**Filing Date:** 2023-3
**Character Count:** 8853
**Document Hash:** 58bb8de119af7bff82dbfef0d83530b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-007273.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0001062993-23-007273

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230315

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adastra Holdings Ltd.
- **CENTRAL INDEX KEY:** 0001891512
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 120909627
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56365
- **FILM NUMBER:** 23746237

**BUSINESS ADDRESS:**
- **STREET 1:** 5451 - 275 STREET
- **CITY:** LANGLEY
- **STATE:** A1
- **ZIP:** V4W3X8
- **BUSINESS PHONE:** 778-715-5011

**MAIL ADDRESS:**
- **STREET 1:** 5451 - 275 STREET
- **CITY:** LANGLEY
- **STATE:** A1
- **ZIP:** V4W3X8

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the date of <u>March 15, 2023</u>

Commission File Number <u>000-56365</u>

<u>**Adastra Holdings Ltd.**</u>

(Translation of registrant's name into English)

<u>**5451 - 275 Street, Langley, British Columbia Canada V4W 3X8**</u>

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]

**Note**: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

------

<u>**SUBMITTED HEREWITH**</u>

[99.1](exhibit99-1.htm) [News Release dated March 15, 2023](exhibit99-1.htm) <br>[99.2](exhibit99-2.htm) [Material Change Report dated March 20, 2023](exhibit99-2.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Adastra Holdings Ltd.**

---

| |
|:---|
| */s/ Michael Forbes* |
| Michael Forbes, Chief Executive Officer |
| Date: March 20, 2023 |

---

------

## Exhibit 99.1

------

![](exhibit99-1x001.jpg)

**NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR<br>DISSEMINATION IN THE UNITED STATES**

**Adastra to Defend Lawsuit**

**LANGLEY, BC, March 15, 2023** - Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) ("**Adastra**" or the "**Company**"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, advises that it has been served with a civil claim filed in the Supreme Court of British Columbia pursuant to the Class Proceedings Act, R.S.B.C. 1996, c. 50 alleging that the Company's press release of February 22, 2023 (the "**Press Release**") misstated certain material facts which mislead the plaintiff in the claim. The suit also names the Company's subsidiary Adastra Labs Inc. and the Company's Chief Executive Officer Mr. Michael Forbes.

The Company denies the allegations in the claim and specifically that the Press Release was misleading and intends to vigorously defend against these allegations should the class action be certified.

Currently, no specific amount of damages is claimed.

**About Adastra Holdings Ltd.**

Adastra has become one of Canada's leaders in the supply and manufacturing of ethnobotanical and cannabis products for lawful adult-use. It serves medical markets and engages in forward-looking therapeutic applications. With cannabis concentrate products sold through retailers at more than 1,600 locations across Canada, Adastra's Phyto Extractions and Endgame Extracts brands are now well established with a solid distribution presence. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. Adastra partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market, with the ultimate aim of addressing the needs of patients. For more information, visit: <u>www.adastraholdings.ca.</u>

**Contacts**

Michael Forbes, CEO, Corporate Secretary & Director

(778) 715-5011

<u>michael@adastraholdings.ca</u>

Alyssa Barry, Media & Investor Relations

(604) 997- 0965

<u>ir@adastraholdings.ca</u>

------

***Forward-Looking Information***

*This news release contains forward-looking information within the meaning of Canadian securities legislation concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include: changes in the laws and underlying regulations governing drugs in Canada; the availability of a qualified workforce; changes in regulations or licensing affecting the Company's business; patient's access to products containing controlled substances and other factors beyond the control of the Company. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.*

------

## Exhibit 99.2

------

**FORM 51-102F3** <br>**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company** 

Adastra Holdings Ltd. (the "**Company**")<br>5451 - 275 Street<br>Langley, BC V4W 3X8

**Item 2. Date of Material Change** 

March 15, 2023

**Item 3. News Release** 

The news release was issued and disseminated via Accesswire on March 15, 2023 and filed on SEDAR at www.sedar.com.

**Item 4. Summary of Material Change** 

The Company advises that it has been served with a civil claim filed in the Supreme Court of British Columbia pursuant to the Class Proceedings Act, R.S.B.C. 1996, c. 50 alleging that the Company's press release of February 22, 2023 (the "**Press Release**") misstated certain material facts which mislead the plaintiff in the claim. The suit also names the Company's subsidiary Adastra Labs Inc. and the Company's Chief Executive Officer Mr. Michael Forbes.

The Company denies the allegations in the claim and specifically that the Press Release was misleading and intends to vigorously defend against these allegations should the class action be certified.

Currently, no specific amount of damages is claimed.

**Item 5. Full Description of Material Change** 

**5.1 Full Description of Material Change**

The material change is fully described in Item 4 above and in the news release which has been filed on SEDAR.

**5.2 Disclosure for Restructuring Transactions**

Not applicable.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102** 

Not applicable.

**Item 7. Omitted Information** 

None.

------

**Item 8. Executive Officer** 

Michael Forbes, CEO, Corporate Secretary and Director <br>Telephone: (778) 715-5011

**Item 9. Date of Report** 

March 20, 2023

------